Venetoclax (Abt-199) might act as a perpetrator in pharmacokinetic drug–drug interactions

Pharmaceutics

Volumn 8, Issue 1, 2016, Pages

  Weiss, Johanna ^a   Gajek, Thomas ^a   Köhler, Bruno Christian ^a   Haefeli, Walter Emil ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ABT 199; CYPs; Drug transporters; Drug drug interaction; Venetoclax

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; VENETOCLAX;

ABCB1 GENE; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CYP1A1 GENE; CYP1A2 GENE; DRUG BLOOD LEVEL; DRUG EFFICACY; EMBRYO; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PIG; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; SLCO1B1 GENE; TUMOR RESISTANCE; UGT1A3 GENE; UGT1A9 GENE;

EID: 84959361596     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics8010005     Document Type: Article

References (41)

1. Anderson, M.A.; Huang, D.; Roberts, A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin. Hematol. 2014, 51, 219–227. [CrossRef][PubMed]
2. Cang, S.; Iragavarapu, C.; Savooji, J.; Song, Y.; Liu, D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J. Hematol. Oncol. 2015, 8, 129. [CrossRef][PubMed]
3. Roberts, A.W.; Davids, M.S.; Pagel, J.M.; Kahl, B.S.; Puvvada, S.D.; Gerecitano, J.F.; Kipps, T.J.; Anderson, M.A.; Brown, J.R.; Gressick, L.; et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2016, 374, 311–322. [CrossRef][PubMed]
4. Souers, A.J.; Leverson, J.D.; Boghaert, E.R.; Ackler, S.L.; Catron, N.D.; Chen, J.; Dayton, B.D.; Ding, H.; Enschede, S.H.; Fairbrother, W.J.; et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19, 202–208. [CrossRef][PubMed]
5. Schinkel, A.H.; Wagenaar, E.; van Deemter, L.; Mol, C.A.; Borst, P. Absence of the MDR1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Investig. 1995, 96, 1698–1705. [CrossRef][PubMed]
6. Evers, R.; Kool, M.; van Deemter, L.; Janssen, H.; Calafat, J.; Oomen, L.C.; Paulusma, C.C.; Oude Elferink, R.P.; Baas, F.; Schinkel, A.H.; et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Investig. 1998, 101, 1310–1319. [CrossRef][PubMed]
7. Pavek, P.; Merino, G.; Wagenaar, E.; Bolscher, E.; Novotna, M.; Jonker, J.W.; Schinkel, A.H. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 2005, 312, 144–152. [CrossRef][PubMed]
8. Schinkel, A.H.; Wagenaar, E.; Mol, C.A.; van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Investig. 1996, 97, 2517–2524. [CrossRef][PubMed]
9. Boesch, D.; Gavériaux, C.; Jachez, B.; Pourtier-Manzanedo, A.; Bollinger, P.; Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991, 51, 4226–4233. [PubMed]
10. König, J.; Cui, Y.; Nies, A.T.; Keppler, D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 2000, 275, 23161–23168. [CrossRef][PubMed]
11. König, J.; Cui, Y.; Nies, A.T.; Keppler, D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278, G156–G164. [PubMed]
12. Weiss, J.; Theile, D.; Spalwisz, A.; Burhenne, J.; Riedel, K.D.; Haefeli, W.E. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochem. Pharmacol. 2013, 85, 265–273. [CrossRef][PubMed]
13. Harmsen, S.; Koster, A.S.; Beijnen, J.H.; Schellens, J.H.; Meijerman, I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metab. Dispos. 2008, 36, 1166–1171. [CrossRef][PubMed]
14. Gupta, A.; Mugundu, G.M.; Desai, P.B.; Thummel, K.E.; Unadkat, J.D. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor; but not constitutive androstane receptor; mediated CYP3A4 and multidrug resistance transporter 1 induction: Studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab. Dispos. 2008, 36, 1172–1180. [PubMed]
15. Weiss, J.; Herzog, M.; Haefeli, W.E. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur. J. Pharmacol. 2011, 660, 298–304. [CrossRef][PubMed]
16. Brandin, H.; Viitanen, E.; Myrberg, O.; Arvidsson, A.K. Effects of herbal medicinal products and food supplements on induction of CYP1A2; CYP3A4 and MDR1 in the human colon carcinoma cell line LS180. Phytother. Res. 2007, 21, 239–244. [CrossRef][PubMed]
17. Yamasaki, D.; Nakamura, T.; Okamura, N.; Kokudai, M.; Inui, N.; Takeuchi, K.; Watanabe, H.; Hirai, M.; Okumura, K.; Sakaeda, T. Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells. Eur. J. Pharm. Sci. 2009, 37, 126–132. [CrossRef][PubMed]
18. Li, W.; Harper, P.A.; Tang, B.K.; Okey, A.B. Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem. Pharmacol. 1998, 56, 599–612. [CrossRef]
19. Harper, P.A.; Prokipcak, R.D.; Bush, L.E.; Golas, C.L.; Okey, A.B. Detection and characterization of the Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in the human colon adenocarcinoma cell line LS180. Arch. Biochem. Biophys. 1991, 290, 27–36. [CrossRef]
20. Novotna, A.; Pavek, P.; Dvorak, Z. Novel stably transfected gene reporter human hepatoma cell line for assessment of aryl hydrocarbon receptor transcriptional activity: Construction and characterization. Environ. Sci. Technol. 2011, 45, 10133–10139. [CrossRef][PubMed]
21. Fröhlich, M.; Albermann, N.; Sauer, A.; Walter-Sack, I.; Haefel, W.E.; Weiss, J. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem. Pharmacol. 2004, 68, 2409–2416. [CrossRef][PubMed]
22. Weiss, J.; Rose, J.; Storch, C.H.; Ketabi-Kiyanvash, N.; Sauer, A.; Haefeli, W.E.; Efferth, T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 2007, 59, 238–245. [CrossRef][PubMed]
23. Peters, T.; Lindenmaier, H.; Haefeli, W.E.; Weiss, J. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 372, 291–299. [CrossRef][PubMed]
24. Albermann, N.; Schmitz-Winnenthal, F.H.; Z’graggen, K.; Volk, C.; Hoffmann, M.M.; Haefeli, W.E.; Weiss, J. Expression of the drug transporters MDR1/ABCB1; MRP1/ABCC1; MRP2/ABCC2; BCRP/ABCG2; and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 2005, 70, 949–958. [CrossRef][PubMed]
25. König, S.J.; Herzog, M.; Theile, D.; Zembruski, N.; Haefeli, W.E.; Weiss, J. Impact of drug transporters for the cellular resistance towards saquinavir and darunavir. J. Antimicrob. Chemother. 2010, 65, 2319–2328. [CrossRef][PubMed]
26. Dvorak, Z.; Vrzal, R.; Henklova, P.; Jancova, P.; Anzenbacherova, E.; Maurel, P.; Svecova, L.; Pavek, P.; Ehrmann, J.; Havlik, R.; et al. JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem. Pharmacol. 2008, 5, 580–588. [CrossRef][PubMed]
27. Ayed-Boussema, I.; Pascussi, J.M.; Maurel, P.; Bacha, H.; Hassen, W. Zearalenone activates pregnane X receptor; constitutive androstane receptor and aryl hydrocarbon receptor and corresponding phase I target genes mRNA in primary cultures of human hepatocytes. Environ. Toxicol. Pharmacol. 2011, 31, 79–87. [CrossRef][PubMed]
28. Vandesompele, J.; De Preter, K.; Pattyn, F.; Poppe, B.; Van Roy, N.; De Paepe, A.; Speleman, F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3, RESEARCH0034. [CrossRef][PubMed]
29. Weiss, J.; Haefeli, W.E. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab. Dispos. 2006, 34, 203–207. [CrossRef][PubMed]
30. Weiss, J.; Sauer, A.; Divac, N.; Herzog, M.; Schwedhelm, E.; Böger, R.H.; Haefeli, W.E.; Benndorf, R.A. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm. Drug Dispos. 2010, 31, 150–161. [CrossRef][PubMed]
31. Weiss, J.; Theile, D.; Dvorak, Z.; Haefeli, W.E. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolizing enzymes assessed in vitro. Pharmaceutics 2014, 6, 632–650. [CrossRef][PubMed]
32. Schimmer, A.D.; Raza, A.; Carter, T.H.; Claxton, D.; Erba, H.; DeAngelo, D.J.; Tallman, M.S.; Goard, C.; Borthakur, G. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS ONE 2014, 9, e108694. [CrossRef][PubMed]
33. LeBlanc, T.W.; McNeil, M.J.; Kamal, A.H.; Currow, D.C.; Abernethy, A.P. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol. 2015, 16, e333–e341. [CrossRef]
34. Roberts, A.W.; Seymour, J.F.; Brown, J.R.; Wierda, W.G.; Kipps, T.J.; Khaw, S.L.; Carney, D.A.; He, S.Z.; Huang, D.C.; Xiong, H.; et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 2012, 30, 488–496. [CrossRef][PubMed]
35. Konopleva, M.; Pollyea, D.A.; Potluri, J.; Chyla, B.J.; Busman, T.; McKeegan, E.; Salem, A.; Zhu, M.; Ricker, J.L.; Blum, W.; et al. A phase 2 study of venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). Blood 2014, 124, 118.
36. Zhang, L.; Zhang, Y.D.; Strong, J.M.; Reynolds, K.S.; Huang, S.M. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008, 38, 709–724. [CrossRef][PubMed]
37. Läpple, F.; von Richter, O.; Fromm, M.F.; Richter, T.; Thon, K.P.; Wisser, H.; Griese, E.U.; Eichelbaum, M.; Kivistö, K.T. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003, 13, 565–575. [CrossRef][PubMed]
38. Okey, A.B.; Riddick, D.S.; Harper, P.A. The Ah receptor: Mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol. Lett. 1994, 70, 1–22. [CrossRef]
39. Lankisch, T.O.; Gillman, T.C.; Erichsen, T.J.; Ehmer, U.; Kalthoff, S.; Freiberg, N.; Munzel, P.A.; Manns, M.P.; Strassburg, C.P. Aryl hydrocarbon receptor-mediated regulation of the human estrogen and bile acid UDP-glucuronosyltransferase 1A3 gene. Arch. Toxicol. 2008, 82, 573–582. [CrossRef][PubMed]
40. Kalthoff, S.; Ehmer, U.; Freiberg, N.; Manns, M.P.; Strassburg, C.P. Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010, 139, 1699–1710. [CrossRef][PubMed]
41. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer. 2002, 2, 48–58. [CrossRef][PubMed]